Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Romiplostim (Nplate®) and Oprelvekin (Neumega®) Correct Thrombocytopenia in TAR Syndrome (Thrombocytopenia with Absent Radii)

Nicolas Gallastegui, MD, Pamela B. Dudkiewicz, DNP, ARNP, Wenche Jy, PhD, Lawrence L. Horstman, BS, Yeon S. Ahn, MD

Blood (2017) 130 (Supplement 1): 4953.

https://doi.org/10.1182/blood.V130.Suppl_1.4953.4953

Published: 2017

Journal Articles

Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study

Augusto Bramante Federici, MD, Giancarlo Castaman, MD, Alfonso Iorio, MD PhD, Emily Oliovecchio, Prodeswil Investigators

Blood (2015) 126 (23): 759.

https://doi.org/10.1182/blood.V126.23.759.759

Published: 2015

Journal Articles

Effects Of a Novel Ceramic Biomaterial On Immune Modulatory Properties and Differentiation Potential Of Mesenchymal Stromal Cells

Blood (2013) 122 (21): 4858.

https://doi.org/10.1182/blood.V122.21.4858.4858

Published: 2013

Journal Articles

Microporous Biphasic Calcium Phosphate Granules (MBCP®) Retain Immunological Properties of Bone Marrow-Derived Mesenchymal Stromal Cells and Promote Osteoblastic Differentiation

Giulio Bassi, Luciano Pacelli, Cedric Mènard, Francesco Bifari, Luc Sensebé, Frederic Deschaseaux, Fabien Guilloton, Serge Baroth, Pierre Layrolle, Giovanni Pizzolo, Karin Tarte, Mauro Krampera

Blood (2011) 118 (21): 1924.

https://doi.org/10.1182/blood.V118.21.1924.1924

Published: 2011

Journal Articles

Replacement Therapy for Minor Surgery and Invasive Procedures in Factor VII Deficiency: The STER Experience

Blood (2011) 118 (21): 1262.

https://doi.org/10.1182/blood.V118.21.1262.1262

Published: 2011

Journal Articles

Replacement Therapy for Surgery in FVII Deficiency: The Ster Experience Concerning 63 Interventions.

Guglielmo Mariani, MD, Angelika Batorova, MD, Alberto Dolce, PhD, Sergio Siragusa, MD, Mario Lapecorella, MD, Jens Bierre Knudsen, MD, Giovanni Di Minno, MD, Elvira Grandone, MD, Giuseppe Tagariello, MD, AnnaRita Tagliaferri, MD, Guenter K.H. K.H. Auerswald, Sr., MD, Jørgen Ingerslev, MD

Blood (2009) 114 (22): 1290.

https://doi.org/10.1182/blood.V114.22.1290.1290

Published: 2009

Journal Articles

Osteonecrosis of the Jaw Related to Bisphosphonates Therapy in Multiple Myeloma and Metastatic Prostate Cancer Patients. A Latin American Report: An Adverse Event To Look For!!.

Brady Beltran, MD, Luis Riva, MD, Daniel del Carpio, MD, Ivan Fernandez, MD, Luis Vera, MD, Rocio Reategui, MD, Fernando Hurtado de Mendoza, MD, Jorge Castillo, MD, Antonio A. Carrasco-Yalan, MD

Blood (2007) 110 (11): 5162.

https://doi.org/10.1182/blood.V110.11.5162.5162

Published: 2007

Journal Articles

Risk of Thromboembolism after Short-Term Interruption of Warfarin.

David Garcia, MD, Elaine Hylek, MD

Blood (2006) 108 (11): 625.

https://doi.org/10.1182/blood.V108.11.625.625

Published: 2006

Journal Articles

von Willebrand Factor/Factor VIII Concentrate (Humate-P®) Is Safe and Effective in the Prevention of Perioperative Bleeding in Patients with Very Low von Willebrand Factor: Ristocetin Cofactor (VWF:RCo).

Joan Cox Gill, MD, Cindy A. Leissinger, MD, Jorge DiPaola, MD, Jonathan Bernstein, MD, Margaret V. Ragni, MD, Rinah Shopnick, MD, Leonard A. Valentino, MD, Sigurd Knaub, PhD, Carl Friedman, MD

Blood (2006) 108 (11): 4071.

https://doi.org/10.1182/blood.V108.11.4071.4071

Published: 2006

Journal Articles

Bisphosphonates and Osteonecrosis of the Jaws: Incidence in a Homogeneous Series of Patients with Newly Diagnosed Multiple Myeloma Treated with Zoledronic Acid.

Patrizia Tosi, MD, Elena Zamagni, MD, Delia Cangini, MD, Paola Tacchetti, MD, Massimo Offidani, MD, Sonia Ronconi, MD, Giulia Perrone, MD, Michela Ceccolini, MD, Michele Baccarani, MD, Sante Tura, MD, Michele Cavo, MD

Blood (2005) 106 (11): 3461.

https://doi.org/10.1182/blood.V106.11.3461.3461

Published: 2005

Journal Articles

Von Willebrand Factor/Factor VIII Concentrate (Humate-P ® ) for Surgical Prophylaxis of Excessive Bleeding in Patients with Von Willebrand Disease (VWD).

Joan Cox Gill, MD, J. DiPaola, MD, J. Bernstein, MD, C. A. Leissinger, MD, L. Valentino, MD, C. Friedman, MD, S. Knaub

Blood (2005) 106 (11): 1791.

https://doi.org/10.1182/blood.V106.11.1791.1791

Published: 2005

Journal Articles

Efficacy of Alphanate ® (Human Factor VIII/Von Willebrand Factor Concentrate) in Preventing Excessive Bleeding during Surgery or Invasive Procedures in Patients with Congenital Von Willebrand Disease. A Multicenter Retrospective Study.

M. Elaine Eyster, MD, Charles L. Sexauer, MD, Simon Brown, MD, Richard A. Lipton, MD, Craig M. Kessler, MD, Louis M. Aledort, MD, Georges E. Rivard, MD

Blood (2005) 106 (11): 3951.

https://doi.org/10.1182/blood.V106.11.3951.3951

Published: 2005

Journal Articles

A Relatively Low Frequency of Bleeding in Patients with Severe Factor XI Deficiency Who Undergo Surgery Involving Tissues with Low Fibrinolytic Activity Supports on Demand Rather Than Prophylactic Use of Plasma.

Ophira Salomon, MD, David M. Steinberg, Ph.D, Uri Seligsohn, MD

Blood (2005) 106 (11): 4036.

https://doi.org/10.1182/blood.V106.11.4036.4036

Published: 2005

NARROW

Romiplostim (Nplate®) and Oprelvekin (Neumega®) Correct Thrombocytopenia in TAR Syndrome (Thrombocytopenia with Absent Radii)

Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study

Effects Of a Novel Ceramic Biomaterial On Immune Modulatory Properties and Differentiation Potential Of Mesenchymal Stromal Cells

Microporous Biphasic Calcium Phosphate Granules (MBCP®) Retain Immunological Properties of Bone Marrow-Derived Mesenchymal Stromal Cells and Promote Osteoblastic Differentiation

Replacement Therapy for Minor Surgery and Invasive Procedures in Factor VII Deficiency: The STER Experience

Replacement Therapy for Surgery in FVII Deficiency: The Ster Experience Concerning 63 Interventions.

Osteonecrosis of the Jaw Related to Bisphosphonates Therapy in Multiple Myeloma and Metastatic Prostate Cancer Patients. A Latin American Report: An Adverse Event To Look For!!.

Risk of Thromboembolism after Short-Term Interruption of Warfarin.

von Willebrand Factor/Factor VIII Concentrate (Humate-P®) Is Safe and Effective in the Prevention of Perioperative Bleeding in Patients with Very Low von Willebrand Factor: Ristocetin Cofactor (VWF:RCo).

Bisphosphonates and Osteonecrosis of the Jaws: Incidence in a Homogeneous Series of Patients with Newly Diagnosed Multiple Myeloma Treated with Zoledronic Acid.

Von Willebrand Factor/Factor VIII Concentrate (Humate-P ® ) for Surgical Prophylaxis of Excessive Bleeding in Patients with Von Willebrand Disease (VWD).

Efficacy of Alphanate ® (Human Factor VIII/Von Willebrand Factor Concentrate) in Preventing Excessive Bleeding during Surgery or Invasive Procedures in Patients with Congenital Von Willebrand Disease. A Multicenter Retrospective Study.

A Relatively Low Frequency of Bleeding in Patients with Severe Factor XI Deficiency Who Undergo Surgery Involving Tissues with Low Fibrinolytic Activity Supports on Demand Rather Than Prophylactic Use of Plasma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only